Syrah Resources and Tesla Extend Deadline on Graphite Supply Dispute to March 
Tesla Revives Dojo Supercomputer Project With AI5 Chip at the Core 
Jamie Dimon Signals Possible Five More Years as JPMorgan CEO Amid Ongoing Succession Speculation 
U.S. Moves to Expand Chevron License and Control Venezuelan Oil Sales 
Publishers Seek to Join Lawsuit Against Google Over Alleged AI Copyright Infringement 
Google Seeks Delay on Data-Sharing Order as It Appeals Landmark Antitrust Ruling 
Federal Judge Clears Way for Jury Trial in Elon Musk’s Fraud Lawsuit Against OpenAI and Microsoft 
BYD Shares Rise in Hong Kong on Reports of Battery Supply Talks With Ford 
Trump Criticizes NYSE Texas Expansion, Calls Dallas Exchange a Blow to New York 
Baidu Shares Rise in Hong Kong After Apollo Go Robotaxi Launch in Abu Dhabi 
Boeing Reaches Tentative Labor Deal With SPEEA Workers After Spirit AeroSystems Acquisition 
Walmart International CEO Kathryn McLay to Step Down After Two and a Half Years 
Toyota Industries Buyout Faces Resistance as Elliott Rejects Higher Offer 
Micron to Buy Powerchip Fab for $1.8 Billion, Shares Surge Nearly 10% 
Rio Tinto and BHP Agree to Explore Major Iron Ore Collaboration in Pilbara 
White House Pressures PJM to Act as Data Center Energy Demand Threatens Grid Reliability 
Pfizer Inc.'s application for emergency use authorization in the US for its potential coronavirus vaccine will be not earlier than the third week of November.
The US pharmaceutical giant is one of several companies during final-stage clinical trials for potential coronavirus vaccines in the country.
According to Chairman and CEO Albert Bourla, Pfizer may find out later this month whether or not its vaccine can help prevent COVID-19 in at least a majority of those vaccinated.
if data from trials support the move, Pfizer will apply for emergency use authorization in the US after the safety milestone is achieved in the third week of November.
The US Food and Drug Administration requires companies to provide two months of safety data on half of the trial participants following the final dose of the vaccine.
Pfizer, which is developing the vaccine with Germany's BioNTech SE, has agreed to supply Japan with 120 million doses of a vaccine for 60 million people if the development efforts are successful.
Another American pharmaceutical firm Moderna Inc. revealed it wouldn't be ready to seek emergency use authorization before Nov. 25.
US President Donald Trump has been raising expectations that vaccines could be ready before the Nov. 3 presidential election.
